QCDF Name	Measure II	D Measure Title	Measure Description	Denominator	Numerator	Denominator Exclusions	Denominator Exceptions	r Numerator Exclusions		Does this measure belong to another QCDR? If so, which one?	NQF Number (if applicable)	NQS Domain	NQS Domain Rationale	Outcome or High Priority?	High Priority Type	Measure Type	Inverse Measure	Proportional Measure	Continuous Variable Measure	Ratio Measure	If Continuous Variable and/or Ratio is chosen, what would be the range of the score(s)?	Number of performance rates to be submitted	Overall Performance Rate if more than 1 performance rate is to be submitted Specify which of the submitted	Measure Risk- Adjusted	If risk- adjusted, indicate which score is risk-adjusted	Please indicate which specialty/specia lties this measure applies to
OEISNE	OEIS2	[mergent transfer from an outpatient, ambulatory surgical center, or office setting	Rate de emergent transfer fora an ougsatient ASC, cordins estitus an acte care facilitat as a result of an invasive peripheral vascular intervention.	denominator that underwent an invasive peripheral vascular	Patients in the desonitate that required emergent transfer to anote care setting or to a higher level of care within an acute care streng transfer level of care within an acute care streng that any any activate transfer from the analysis of the strength of the strength of the table any any activates transfer from the analysis of the strength of the strength of the D are ortical care from an ambutatory unit within a hospital in order to transfer a compact factory level associated with the IAD prosectors. Proceeder include: Illia, common factorial at strength of the strength of the prosectors. Proceeder include: Illia, common factorial at strength of the strength of percutaneous transformation and pedial strength percutaneous transformation and pedial strength and caccur prior to the patient's discharge from the ambutatory conter.	procedure, planned	None	None	Record review	No		atient afety	There is a measure gap in this clinical performance area	Outcome	N/A	Outcome	Yes	tes	No	No	N/A	1	N/A	No	N/A	
OEISNF	OEIS3	Antiplatelet Therapy	Percentage of patients with PAD that have been prescribed an angulated medication at the reported encounter.		documentation of a prescribed antiplatelet medication. Antiplatelet medications include Aspirin, tickpidine, ticagrafor, prasugrel, and clopidogrel.	Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not prescribing an antiplatelet physician assistant for not prescribing an antiplatelet gent (e.g., allergy or intolerance to either aprint noncompliance, use of warfain or other monompliance, use of warfain or other measuri, for not prescribing an antiplatelet agent (e.g., patient refusa).	None	None	EHR (enter relevant parts in the field below)	No	c	linical	There is currently not a systematic measurement of performance for this guideline recommendation. Multiple studies have identified this as a critical intervention.	N/A	N/A	Process	No	tes	No	No	NA	1	N/A	No	N/A	
OEISNF	OEIS4	Lipid-Lowering Medications for Patients with PAD	peripheral artery disease have documentation of a currently prescribed antihyperlipidemic medication treatment. This may include one	with an encounter during the reporting interval AND Symptomatic PAD. Symptomatic PAD is defined as the presence of 1 or more of the following:		reasons for not prescribing	None	None	Record review	No			There is a measure gap in this area	N/A	N/A	Process	No	(es	No	No	NA	1	N/A	No	N/A	
OEISNE	OEIS6	Appropriate non-invasive arterial testing for patients with intermitten claudication who are undergoing a LE peripheral vascular intervention	Proportion of patients with non-invasive evaluations preserved, and adde prior to Lie peripheral vascular interventions in patients with intermittent claudication.	interval AND PAD with intermittent	Paterts in the denominator that received one of the Glowing examismos, AU/DI articutors, AU/DI articutors, AU/DI articutors, AU/DI articutors, AU/DI articutors, AU/DI articutors, AU/DI articutors, AU/DI articutors, AU/DI articutors, Superficient Augustantin, Stri- tempher State (State State), State (State), State 21 months prior to the most recent Lover Externity Procedure Incident; Billia, Common Innova Inters, superficial femoral articly, Biogenoral Intuna da pelad attray, percutanous translummai arepoptisty starting, alterecture, drug cated balloon, drug exting taxet.	refuses to participate in the	None	None	Record review	No	c	ffective linical are	Measure gap exists in this clinical performance area	N/A	N/A	Process	No	(es	No	No	NA	1	N/A	No	N/A	